SCHEMBL445368

SCHEMBL445368

CCCCOC(CCC)C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 4/20 0.44
PPARA Q07869 4/20 0.44
CHRM1 P11229 1/20 0.43
AKR1A1 P14550 1/20 0.43
CHRM3 P20309 1/20 0.43
HTR2A P28223 1/20 0.43
HTR2C P28335 1/20 0.43
ADRA1A P35348 1/20 0.43
HRH1 P35367 1/20 0.43
DRD3 P35462 1/20 0.43
SLC6A3 Q01959 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC2 Q92769 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
CA2 P00918 1/20 0.42
MAPK1 P28482 1/20 0.42
GPR84 Q9NQS5 3/20 0.41
FFAR1 O14842 1/20 0.41
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12179694 1.00 PPARG (0.44) PPARGPPARACHRM1AKR1A1CHRM3
SCHEMBL5520988 0.94 GPR84 (0.44) PPARGPPARACHRM1AKR1A1CHRM3
SCHEMBL9689010 0.92 GPR84 (0.47) PPARGPPARAGPR84FFAR1MAPT
SCHEMBL10868203 0.92 GPR84 (0.47) PPARGPPARAGPR84FFAR1MAPT
SCHEMBL10867517 0.92 GPR84 (0.47) PPARGPPARAGPR84FFAR1MAPT
SCHEMBL10865023 0.92 GPR84 (0.47) PPARGPPARAGPR84FFAR1MAPT
SCHEMBL9687901 0.92 GPR84 (0.47) PPARGPPARAGPR84FFAR1MAPT
SCHEMBL5519540 0.92 GPR84 (0.47) PPARGPPARAGPR84FFAR1MAPT
SCHEMBL9688426 0.92 GPR84 (0.47) PPARGPPARAGPR84FFAR1MAPT
SCHEMBL10867810 0.92 GPR84 (0.47) PPARGPPARAGPR84FFAR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050267168-A1 Pentanoic acid derivatives ONO PHARMACEUTICAL CO., LTD. 2005-12-01 US claimed
CN-1200703-C Use of pentanoate derivant ONO PHARMACEUTICAL CO (JP) 2005-05-11 CN claimed
US-20030096802-A1 Pentanoic acid derivatives ONO PHARMACEUTICAL CO., LTD. 2003-05-22 US claimed
CN-1322524-A Use of pentanoate derivant ONO PHARMACEUTICAL CO (JP) 2001-11-21 CN claimed
US-6201021-B1 TREATMENT OF DISEASES INDUCED BY REACTIVE ASTROCYTES ONO PHARMACEUTICAL CO., LTD. (JP) 2001-03-13 US claimed
EP-0632008-B1 Pentanoic acid derivatives ONO PHARMACEUTICAL CO (JP) 1998-02-04 EP claimed
CN-1100408-A Pentanoic acid derivatives ONO PHARMACEUTICAL CO (JP) 1995-03-22 CN claimed
EP-0632008-A1 Pentanoic acid derivatives ONO PHARMACEUTICAL CO., LTD. (JP) 1995-01-04 EP claimed
EP-0175591-A2 Lactic acid derivative, liquid crystal composition containing same and liquid crystal device CANON KABUSHIKI KAISHA (JP) 1986-03-26 EP claimed
JP-61076438-A None JP disclosed
US-10916437-B2 Methods of forming micropatterns and substrate processing apparatus SAMSUNG ELECTRONICS CO., LTD. (KR) 2021-02-09 US disclosed
US-20190198342-A1 Methods of Forming Micropatterns and Substrate Processing Apparatus SAMSUNG ELECTRONICS CO., LTD. (KR) 2019-06-27 US disclosed
US-10134606-B2 Method of forming patterns and method of manufacturing integrated circuit device using the same SAMSUNG ELECTRONICS CO., LTD. (KR) 2018-11-20 US disclosed
US-9773672-B2 Method of forming micropatterns SAMSUNG ELECTRONICS CO., LTD. (KR) 2017-09-26 US disclosed
US-4882085-A Lactic acid derivative and liquid crystal composition containing same CANON KABUSHIKI KAISHA (JP) 1989-11-21 US disclosed
US-4812585-A REACTING A FURAN COMPOUND WITH A MIXED ACID ANHYDRIDE IN THE PRESENCE OF A BORON TRIFLUORIDE COMPLEX CATALYST SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1989-03-14 US disclosed
US-4775223-A DISPLAY DEVICE CANON KABUSHIKI KAISHA (JP) 1988-10-04 US disclosed
EP-0268820-A2 Process for producing 2-acylfuran derivatives SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1988-06-01 EP disclosed
JP-S6176438-A LACTIC ACID DERIVATIVE AND ITS COMPOSITION CANON INC 1986-04-18 JP disclosed
EP-0175591-A2 Lactic acid derivative, liquid crystal composition containing same and liquid crystal device CANON KABUSHIKI KAISHA (JP) 1986-03-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050267168-A1 Pentanoic acid derivatives FFAR3, FFAR1, HCAR3 PPARG 510/4885PPARA 540/4885CHRM1 93/4885
US-20030096802-A1 Pentanoic acid derivatives FFAR3, FPR1, FPR3 PPARG 932/4885PPARA 796/4885CHRM1 84/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.